当前位置: X-MOL 学术Brachytherapy › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Viability of focal dose escalation to prostate cancer intraprostatic lesions using HDR prostate brachytherapy
Brachytherapy ( IF 1.9 ) Pub Date : 2023-09-23 , DOI: 10.1016/j.brachy.2023.09.001
Joel Poder 1 , Samantha Radvan 2 , Andrew Howie 3 , Farshad Kasraei 3 , Annaleise Parker 3 , Joseph Bucci 3 , Annette Haworth 2
Affiliation  

PURPOSE

This study aimed to determine the viability of focal dose escalation to prostate cancer intraprostatic lesions (IPLs) from multiparametric magnetic resonance (mpMRI) and prostate-specific membrane antigen positron emission tomography (PSMA-PET) images using high-dose-rate (HDR) prostate brachytherapy (pBT).

METHODS AND MATERIALS

Retrospective data from 20 patients treated with HDR pBT was utilized. The interobserver contouring variability of 5 observers was quantified using the dice similarity coefficient (DSC) and mean distance to agreement (MDA). Uncertainty in propagating IPL contours to trans-rectal ultrasound (TRUS) was quantified using a tissue equivalent prostate phantom. Feasibility of incorporating IPLs into HDR pBT planning was tested on retrospective patient data.

RESULTS

The average observer DSC was 0.65 (PSMA-PET) and 0.52 (mpMRI). The uncertainty in propagating IPL contours was 0.6 mm (PSMA-PET), and 0.4 mm (mpMRI). Uncertainties could be accounted for by expanding IPL contours by 2 mm to create IPL PTVs. The mean D98% achieved using HDR pBT was 166% and 135% for the IPL and IPL PTV contours, respectively.

CONCLUSIONS

Focal dose escalation to IPLs identified on either PSMA-PET or mpMRI is viable using TRUS-based HDR pBT. Utilizing HDR pBT allows dose escalation of up to 166% of the prescribed dose to the prostate.



中文翻译:

使用 HDR 前列腺近距离放射治疗对前列腺癌前列腺内病变进行局部剂量递增的可行性

目的

本研究旨在通过使用高剂量率 (HDR) 的多参数磁共振 (mpMRI) 和前列腺特异性膜抗原正电子发射断层扫描 (PSMA-PET) 图像确定局部剂量递增对前列腺癌前列腺内病变 (IPL) 的可行性前列腺近距离放射治疗(pBT)。

方法和材料

使用了 20 名接受 HDR pBT 治疗的患者的回顾性数据。使用骰子相似系数 (DSC) 和平均一致性距离 (MDA) 量化 5 名观察者的观察者间轮廓变异性。使用组织等效前列腺模型对将 IPL 轮廓传播到经直肠超声 (TRUS) 的不确定性进行量化。根据回顾性患者数据测试了将 IPL 纳入 HDR pBT 计划的可行性。

结果

观察者平均 DSC 为 0.65 (PSMA-PET) 和 0.52 (mpMRI)。传播 IPL 轮廓的不确定性为 0.6 毫米 (PSMA-PET) 和 0.4 毫米 (mpMRI)。可以通过将 IPL 轮廓扩展 2 毫米来创建 IPL PTV 来解决不确定性。对于 IPL 和 IPL PTV 轮廓,使用 HDR pBT 实现的平均 D98% 分别为 166% 和 135%。

结论

使用基于 TRUS 的 HDR pBT 可以将局部剂量升级至 PSMA-PET 或 mpMRI 上确定的 IPL。利用 HDR pBT 可使前列腺剂量增加高达处方剂量的 166%。

更新日期:2023-09-23
down
wechat
bug